Infographic: Gyrolab® hybridization assays for oligonucleotide analysis
This infographic provides an overview of oligonucleotide therapies and highlights their development since the first FDA-approved oligo in 1998. We summarize the Gyrolab hybridization assay design and the benefits of using Gyrolab microfluidic immunoassays to overcome issues associated with manual assay pipetting and incubation steps. Finally, we explore how Gyrolab’s fully automated hybridization-based oligonucleotide therapy quantitation assay helps to meet the increasing demand for improved approaches to oligonucleotide therapeutic bioanalysis, expanding the landscape of genetic disease therapeutics.
[Illustrated by Tobias Dumbraveanu]
In association with:
